Design RNA therapeutics with explainable AI.

Your partner for precise and exceptional designs.

Proven team, technology, and results.

Abzu delivers groundbreaking RNA therapeutic designs for pharma, biotech, and research institutions.

Leading in short oligonucleotide innovation and design.

Precision RNA therapeutics with ASOs, siRNAs, and antimiRs.

We’re redefining the potential of RNA therapeutics through our specialized workflow with ASOs, siRNAs, and antimiRs.

This focus ensures our therapeutics have high activity and exhibit minimal off-target effects, heralding a new era of precision medicine.

Abzu’s measurable impact in RNA therapeutic design.

Where proven results speak louder than promises, Abzu stands apart.

Abzu designed active and safe ASO and siRNA therapeutics.

A strategic partnership with Contera Pharma included ASO and siRNA therapeutic designs and target identification.

Abzu created a real-time LNP designer to predict apparent pKa value.

Our models, interfaced through an application, allowed scientists to modify LNP properties and observe the direct impact.

Abzu increased safe ASOs by 20% over-and-above the in-house model.

Abzu's in-house activity models for RNA therapeutics are best-in-class for designing safe ASOs.

Abzu is your partner in RNA therapeutics design.

A cycle of innovation and optimization — to RNA therapeutics realization.

Whether we start with designs or your data, Abzu provides you the insights and confidence to accelerate your R&D and transform concepts into market-ready drugs.

The latest in research, perspective, and events.

Your next RNA therapeutics design insight starts here.

Designing active and safe siRNA with siRNA activity models.

Here we use the QLattice® to generate siRNA activity models from publicly available data to create insights that can be used to design active siRNAs.

Could Artificial Intelligence Provide the Key to Life Saving Medicines?

Since a key challenge in designing oligonucleotides is the potential for toxicity, especially at high doses, using machine learning to mitigate this challenge would be an enormous benefit to oligonucleotide medicines.

RNA Leaders Europe Congress 2024: Presentation in Basel.

RNA Leaders Europe is the #1 event focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids & RNA targets.

Less data, more discovery.

Make the most out of every piece of information.

Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.

Let's unlock the future of RNA therapeutics together.

But first: Tell us about your scientific and business objectives.

Let’s have a conversation about your targets, therapies, and goals. If you want to transcend insufficient analytics and black-box AI, then please complete the form below — we look forward to chatting!

Entering your information above does not subscribe you to marketing emails from Abzu. It just makes it easier for us to get in touch with you. If you want to subscribe for information from Abzu, you can subscribe here.

Abzu is making headlines.

Abzu's innovative work in RNA therapeutics makes waves in the scientific community and beyond.

Pharmafocus
February 7, 2024

Don’t settle for black box: Why only explainable AI is built for pharma.

IPT
June 12, 2023

AI in Pharma: Balancing Reality with Possibility.

Sifted
May 5, 2023

20 Nordic startups to watch, according to investors.

OTS
May 9, 2022

Could Artificial Intelligence Provide the Key to Life Saving Medicines?

Subscribe for
notifications from Abzu.

You can opt out at any time. We’re cookieless, and our privacy policy is actually easy to read.

Design RNA therapeutics with explainable AI.

Your partner for precise and exceptional designs.

Proven team, technology, and results.

Abzu delivers groundbreaking RNA therapeutic designs for pharma, biotech, and research institutions.

Leading in short oligonucleotide innovation and design.

Precision RNA therapeutics with ASOs, siRNAs, and antimiRs.

Abzu’s measurable impact in RNA therapeutic design.

Where proven results speak louder than promises, Abzu stands apart.

Abzu designed active and safe ASO and siRNA therapeutics.

Abzu created a real-time LNP designer to predict apparent pKa value.

Abzu increased safe ASOs by 20% over-and-above the in-house model.

Abzu is your partner in RNA therapeutics design.

A cycle of innovation and optimization — to RNA therapeutics realization.

The latest in research, perspective, and events.

Your next RNA therapeutics design insight starts here.

Designing active and safe siRNA with siRNA activity models.

Could Artificial Intelligence Provide the Key to Life Saving Medicines?

RNA Leaders Europe Congress 2024: Presentation in Basel.

Less data, more discovery.

Make the most out of every piece of information.

Let's unlock the future of RNA therapeutics together.

But first: Tell us about your scientific and business objectives.

Abzu is making headlines.

Abzu's innovative work in RNA therapeutics makes waves in the scientific community and beyond.

Subscribe fornotifications from Abzu.

Subscribe for
notifications from Abzu.